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Abstract
Over the last 50 years, while significant ad-
vances have been made in the successful treat-
ment of childhood leukaemia, similar progress
has been made in understanding the genetics
of the disease. In childhood B-cell precursor
acute lymphoblastic leukaemia (BCP-ALL), the
incidences of individual chromosomal abnor-
malities are well established and cytogenetics
provides a reliable tool for risk stratification
for treatment. In spite of this role, a number of
patients  will  relapse.  Increasing  numbers  of
additional  genetic  changes,  including  dele-
tions  and  mutations,  are  being  discovered.
Their  associations  with  established  cytoge-
netic subgroups and with each other remain
unclear. Whether they have a link to outcome
is the most important factor in terms of refine-
ment of risk factors in relation to clinical trials.
For a number of newly identified abnormali-
ties, appropriately modified therapy has signif-
icantly improved outcome. Alternatively, some
of these aberrations are providing novel molec-
ular markers for targeted therapy.
Introduction
In  childhood  B-cell  precursor  acute  lym-
phoblastic leukaemia (BCP-ALL), the incidences
of  individual  chromosomal  abnormalities  are
well  established,  with  high  hyperdiploidy  and
the  translocation,  t(12;21)(p13;q22),  together
comprising more than 50% of cases. Other ab-
normalities,  for  example  the  translocation,
t(9;22)(q34;q11), and rearrangements of the
MLL gene, are rare in childhood BCP-ALL. It is
also  known  that  the  distribution  of  chromo-
somal changes varies according to age, with
teenagers and young adults having the highest
incidence of ill-defined abnormalities.1 Partic-
ularly in BCP-ALL, chromosomal abnormalities
remain strong independent indicators of risk
of relapse.2
Structural chromosomal 
abnormalities in BCP-ALL
Those  structural  abnormalities  with  the
most significant impact for risk stratification
for treatment are t(9;22)(q34;q11)/BCR-ABL1
and rearrangements of the MLL gene. In par-
ticular  this  applies  to  t(4;11)(q21;q23)/MLL-
AFF1 (previously  known  as  MLL-AF4).  The
prognosis of the other MLL partners may be-
come  significant  in  the  future,  particularly
among infants.3 The detection of these two ab-
normalities provides the basic criteria for the
classification of high risk groups, which is ap-
plicable to all treatment protocols. Other sig-
nificant  structural  abnormalities  include
t(12;21)(p13;q22)/ETV6-RUNX1 fusion, as well
as t(1;19)(q23;p13.3)/TCF3-PBX1 fusion. How-
ever, these are not used in risk stratification
on all protocols. The ETV6-RUNX1 fusion oc-
curs in approximately 25% of younger children
with  BCP-ALL.  These  patients  have  an  ex-
tremely good prognosis Among patients with
TCF3 rearrangements, those with TCF3-PBX1
were originally regarded as poor risk on some
treatment  protocols,  but  on  modern  therapy
they are classified as standard risk.4,5 In con-
trast, the rare variant, t(17;19)(q22;p13)/HLF-
TCF3 fusion, has a dismal outcome on all ther-
apies.6 Thus its accurate identification is im-
portant.
Numerical chromosomal abnormal-
ities in BCP-ALL
Significant numerical abnormalities include
high hyperdiploidy (51-65 chromosomes),7near-
haploidy  (24-29  chromosomes)  and  low  hy-
podiploidy (31-39 chromosomes).8,9 High hyper-
diploidy  accounts  for  approximately  30%  of
childhood BCP-ALL and is characterised by the
gain of specific chromosomes. It is associated
with a good prognosis in children. Near-haploidy
and low hypodiploidy are rare, comprising <1%
each of childhood ALL. Their characteristic fea-
tures are the gain of specific chromosomes onto
the haploid chromosome set and, in the majority
of patients, the presence of a population of cells
with  an  exact  doubling  of  this  chromosome
number.8 Both are linked to a poor outcome and
are used to stratify patients as high risk.
Submicroscopic abnormalities in
BCP-ALL
A significant discovery was the finding that
the disruption of genes involved in B-cell de-
velopment played an important role in leukae-
mogenesis  in  childhood  BCP-ALL.10 Approxi-
mately 40% of these patients had abnormali-
ties of genes involved in the B-cell develop-
mental  pathway:  PAX5,  TCF3,  EBF1,  LEF1,
IKZF1 and IKZF3. Other genes frequently af-
fected  were  those  controlling  cell  cycle  pro-
gression:  CDKN2A,  CDKN1B and  RB1.11,12
Many  of  these  deletions  can  be  detected  by
FISH and/or genomic arrays. Whether there is
a link between these genes and outcome has
become a critical question.13 In particular, the
association  of  IKZF1 deletions  with  a  poor
prognosis14,15 requires  further  validation  in
prospective, independent and unselected trial-
based patient cohorts.
What can be the impact 
of discovering a new genetic 
abnormality?
Intrachromosomal amplification 
of chromosome 21- iAMP21
The  cytogenetic  subgroup,  iAMP21  (intra-
chromosomal  amplification  of  chromosome
21), was identified during routine screening
for the presence of the ETV6-RUNX1 fusion by
fluorescence in situ hybridization (FISH).16,17
Patients are negative for the ETV6-RUNX1 fu-
sion,  while  in  addition  to  the  two  normal
copies  of  the  ETV6 signal,  show  multiple
RUNX1 signals (3 or more additional signals)
with this probe. In metaphase, one signal is lo-
cated to the normal chromosome 21, while the
others are seen in tandem duplication along an
abnormal chromosome 21.18 In interphase, the
signals are clustered together, except for one
signal  representing  the  normal  chromosome
21,  which  is  usually  located  apart.  Cytoge-
netics, multiple colour FISH and high resolu-
tion genomic arrays have shown that the mor-
phology  of  the  abnormal  chromosome  21  is
highly  variable  between  patients,  with  mul-
tiple, complex genomic rearrangements, and
that the commonly amplified region always in-
cludes the RUNX1 gene.18-20 This abnormality
was originally described as poor risk on stan-
dard  therapy,17,18,21,22 although  the  outcome
has  since  been  shown  to  be  protocol  de-
pendent.23,24 Thus its accurate detection is im-
portant to guide therapy, at least in some pro-
tocols. Currently FISH with probes directed to
RUNX1 remain  the  only  reliable  detection
method. Studies are continuing to determine
the mechanism(s) underlying this unusual ab-
normality in order to develop an improved di-
agnostic test.
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IGH@ translocations
Translocations involving IGH@ at 14q32 are
emerging as a significant subgroup in child-
hood  BCP-ALL,  at  an  incidence  of  approxi-
mately  8%.  Translocations  involving  IGH@
with five genes from the CEBP gene family,
ID4 and the cytokine receptor to erythropoi-
etin, EPOR, have recently been described.25-28
It is of interest that they occur more frequently
in  adolescents  and,  although  numbers  are
small, they appear to have an inferior outcome.
Recently,  a  cryptic  translocation,  t(X;14)
(p22;q32) or t(Y;14)(p11;q32), involving IGH@
and  CRLF2  in  the  pseudoautosomal  region
(PAR1) of the sex chromosomes,29 and a dele-
tion  within  PAR1,  giving  rise  to  the P2RY8-
CRLF2 fusion,  have  been  reported.29-32 They
lead to overexpression of CRLF2 at both the
transcript and protein levels, which has been
defined as a novel, significant abnormality in
BCP-ALL.  CRLF2  alterations,  including  acti-
vating mutations of the CRLF2 receptor itself,
are associated with activating JAK mutations
resulting in constitutive activation of the JAK-
STAT signalling pathway and they are particu-
larly  common  in  Down  syndrome  ALL.29,31-33
Activation of this pathway has been associated
with a worse prognosis in adults and children
in  some  trials,34,35 although  not  in  others.36
Nevertheless,  it  has  been  highlighted  as  an
important consideration for targeted therapy.
Following further validation, the detection of
CRLF2 alterations may become a necessary di-
agnostic test.
In  childhood  ALL,  interest  in  mutations
within genes involved in key cellular pathways
is heightening as deep-sequencing techniques
are becoming established.37 A number of asso-
ciations  with  other  genetic  changes  are  al-
ready known, such as the link between muta-
tions  of  genes  within  the  RAS  signalling
pathway and high hyperdiploidy.38,39 The diffi-
culty lies in unravelling the relationships be-
tween the expanding numbers of abnormali-
ties. It is likely that whole genome sequencing
approaches  to  detect  submicroscopic  re-
arrangements together with mutations will be-
come more commonplace within the arena of
genetic research within the near future.
Current research is directed towards deter-
mining the prognostic significance of the re-
cently described genomic abnormalities on the
background  of  established  aberrations  with
the aim of predicting all patients at risk of re-
lapse. The task is not simple due to the ever in-
creasing numbers of all types of lesions and
the complexity of their interactions. However,
the goal to be achieved in the near future is to
generate a personal genetic profile for each pa-
tient from which appropriate molecular targets
will emerge, leading to the provision of individ-
ualised treatment with reduced morbidity and
further improved outcome.
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